CN Patent

CN112194681A — 核苷酸长链氨基磷酸酯化合物、其药物组合物及其制备方法和应用

Assigned to Foshan University · Expires 2021-01-08 · 5y expired

What this patent protects

本发明属于医药技术领域，公开了核苷酸长链氨基磷酸酯化合物、其药物组合物及其制备方法和应用，特别是作为治疗新冠肺炎的用途。试验证明本发明的核苷酸长链氨基磷酸酯化合物具有抑制2019‑nCoV病毒复制的活性，同时所述核苷酸长链氨基磷酸酯化合物具有比目前治疗新冠肺炎药物瑞德西韦体外活性高、开发系数大等优点，可用于治疗新冠肺炎药物的开发。

USPTO Abstract

本发明属于医药技术领域，公开了核苷酸长链氨基磷酸酯化合物、其药物组合物及其制备方法和应用，特别是作为治疗新冠肺炎的用途。试验证明本发明的核苷酸长链氨基磷酸酯化合物具有抑制2019‑nCoV病毒复制的活性，同时所述核苷酸长链氨基磷酸酯化合物具有比目前治疗新冠肺炎药物瑞德西韦体外活性高、开发系数大等优点，可用于治疗新冠肺炎药物的开发。

Drugs covered by this patent

Patent Metadata

Patent number
CN112194681A
Jurisdiction
CN
Classification
—
Expires
2021-01-08
Drug substance claim
No
Drug product claim
No
Assignee
Foshan University
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.